intestinal pseudoobstruction

(redirected from Gastrointestinal dysmotility)

in·tes·ti·nal pseu·do·ob·struc·tion

clinical manifestations falsely suggesting obstruction of the small intestine, usually occurring in patients with multiple jejunal diverticula.

intestinal pseudoobstruction

Etymology: L, intestinum, intestine; Gk, pseudes, false; L, obstruere, to build against
a condition characterized by constipation, colicky pain, and vomiting, but without evidence of organic obstruction apparent at laparotomy.
References in periodicals archive ?
Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants.
These features, which include cutaneous flushing, certain chronic pain disorders, autonomic dysfunction, and gastrointestinal dysmotility, have been associated with genetic disorders or joint hypermobility syndromes.
A four-year-old girl ex pre-term with gastrointestinal dysmotility and global developmental delay requires her tube due to mild laryngomalacia and aspiration with thin fluids.
Several years later, another study, (4) which described a group of 24 patients with clinically demonstrated gastrointestinal dysmotility, nocturnal awakening attributed to uncontrolled asthma, elevated histamine levels, and a history of food or environmental allergy, was published.
Perhaps the most obvious influence on gastrointestinal dysmotility is that of the inflammatory cytokines common to the normal stress response present in all critically ill patients.
Ulimorelin is currently entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
Gastrointestinal neuromuscular disease (GINMD) represents an evolving spectrum of gastrointestinal disorders associated with symptoms of chronic gastrointestinal dysmotility in both pediatric and adult populations.
Gastrointestinal dysmotility and Helicobacter pylori infection have been cited as other possible associations.
The paper, "Cholinergic Autonomic Dysfunction in Veterans with Gulf War Illness," revealed a blunting or loss of normal nighttime parasympathetic activity in veterans suffering from Gulf War Illness was strongly associated with upper gastrointestinal dysmotility and sleep dysfunction.
TZP-102 is an oral ghrelin agonist with potent prokinetic properties currently in clinical development for the treatment of chronic gastrointestinal dysmotility disorders such as gastroparesis, functional dyspepsia, and refractory GERD.
Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

Full browser ?